All In MedTech

Device Trial Radar · NCT01110681

Study to Evaluate Solesta for Treatment of Fecal Incontinence

An Open, Non-comparative, Post-marketing, Multi-center Study to Evaluate Efficacy and Safety of SolestaTM for the Treatment of Fecal Incontinence

Last checked: Nov 19, 2026Latest source record: Aug 26, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

115

Actual

Start

Nov 2007

Primary completion

Nov 2009

Study completion Dec 2010

Sponsor

Lead sponsor
Galderma R&DNot on our public-company list
Sponsor type
Industry
First posted
Apr 27, 2010

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will evaluate the safety and efficacy of Solesta as an injectable bulking agent in the treatment of fecal incontinence for a total of 24 months after completed treatment.

Conditions

  • Fecal Incontinence

Interventions

  • Solesta (Dextranomer in gel of stabilized non-animal hyaluronate)Device

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Responder Rate in Number of Fecal Incontinence EpisodesTime frame: 12 months after last treatment compared to baseline

Locations

15 sites in 7 countries. Site status is shown where the registry gives one.

  • St. Paul's Hospital

    Vancouver, Canada

  • Helsingin yliopistollinen keskussairaala

    HUS, Finland

  • CHU-Hotel-Dieu

    Nantes, France

12 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.